<h2>为什么住友化学最新的财报对投资者很重要</h2>
<p>住友化学公司（TSE:4005）刚刚公布了全年的财报，显示出净收入和每股收益的增长，尽管销售额有所下降，这得益于外汇收益以及农业与生命解决方案和信息通信与移动解决方案的贡献。</p>
<p>查看我们对住友化学公司的最新分析。</p>
<p>在财报发布后，股价回落了 3.66%，1 天的股价回报为¥600.8，但年初至今的股价回报为 32.98%，1 年的总股东回报为 81.34%，这表明随着投资者重新评估盈利质量、货币敏感性以及近期计划的 Koei Chemical 股权交换等举措，市场动能正在积聚。</p>
<p>如果住友化学的反弹引起了你的注意，这可能是考虑其他机会的好时机。考虑使用我们对 34 只电网技术和基础设施股票的筛选器，以寻找与基础设施和材料需求相关的潜在长期主题。</p>
<p>市场反应强劲，但该股仍仅略低于最新的分析师目标价，并且似乎存在显著的内在折扣。这引发了一个问题：这是一个真正的机会，还是未来的增长已经被定价？</p>
<h2>最受欢迎的叙述：高估 2%</h2>
<p>最受关注的叙述将住友化学的公允价值定为¥589.7，略低于最后收盘价¥600.8。这意味着只有适度的溢价，并将焦点完全放在该数字背后的盈利和利润率故事上。</p>
<blockquote>
<p><em>关键领域（农业与生命解决方案、基本与绿色材料、信息通信与移动解决方案）盈利能力的恢复反映了运营效率的提高、产品组合的优化以及以研发驱动的新产品推出（例如，Orgovyx、Gemtesa、INDIFLIN），支持长期收入和净利润率的提升潜力。</em></p>
</blockquote>
<p><em>阅读完整叙述。</em></p>
<p>分析师们预计稳定的收入、略微收窄的利润率和更高的未来盈利倍数，所有这些都经过 7.9% 的折现率过滤。这引发了一个问题：哪些增长、盈利能力和估值假设需要对齐，以使该公允价值保持稳定。</p>
<p><strong>结果：公允价值为¥589.7（高估）</strong></p>
<p>完整阅读叙述，了解预测背后的原因。</p>
<p>然而，明显存在压力点，包括石化利润率疲软和农业与生命解决方案库存上升，这可能会挑战投资者关注的盈利和估值叙述。</p>
<p>了解住友化学公司叙述的关键风险。</p>
<h2>另一种观点：盈利能力与市场倍数</h2>
<p>分析师认为住友化学在其盈利模型下高估 2%，公允价值为¥589.7，而该股的市盈率为 16.3 倍，JP 化学平均为 14.2 倍，公允比率为 20.3 倍。这个差距暗示了上行潜力和重新评级风险。你站在哪一边？</p>
<p>查看数字对这一价格的看法——在我们的估值分析中了解更多。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b80c179c-5115-4da9-9663-b331424c1556/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTE4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b80c179c-5115-4da9-9663-b331424c1556/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTE4"/></p>
<p>截至 2026 年 5 月的 TSE:4005 市盈率</p>
<h2>下一步</h2>
<p>如果这里的风险与回报的组合感觉微妙平衡，不要等到人群为你做决定。查看 3 个关键回报和 3 个重要警告信号的完整分析。</p>
<h2>寻找更多投资想法？</h2>
<p>如果住友化学已经在你的雷达上，不要止步于此。市场上还有其他股票可能更符合你的风险和回报偏好。</p>
<ul>
<li>通过审查被标记为 19 只高质量低估股票的公司，目标长期复合潜力，这些公司有坚实的盈利支持和改善情绪的空间。</li>
<li>通过扫描 41 只高股息股票来增强你的收入流，这些股票结合了更高的收益率和专注于维持定期支付的商业模式。</li>
<li>通过检查包含 55 只高质量未被发现的宝藏的筛选器，抢先于人群，这些股票的强大基本面尚未吸引广泛的市场关注。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不应被视为财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们的目标是为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新功能：在一个地方管理所有股票投资组合</strong></h3>
<p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>而且是免费的。</strong></p>
<p>• 连接无限数量的投资组合，并以一种货币查看你的总额</p>
<p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
<p>• 跟踪你股票的公允价值</p>
<p>免费试用演示投资组合</p>

4005

<p>住友化学（TSE:4005）报告称，尽管销售额下降，但净收入和每股收益有所上升，这得益于外汇收益。财报发布后，股价下跌 3.66%，至 600.8 日元，但年初至今的回报率为 32.98%。分析师认为该股在 589.7 日元的公允价值下被高估 2%，并指出了如石化利润率疲软等风险。该股的市盈率为 16.3 倍，高于行业平均水平，暗示潜在的上涨空间，但也存在重新评级的风险。投资者被鼓励在市场中探索其他机会</p>

<h2>Why Sumitomo Chemical's Latest Earnings Matter For Investors</h2>
<div class="lb-trans"><h2>为什么住友化学最新的财报对投资者很重要</h2>
</div><p>Sumitomo Chemical Company (TSE:4005) just reported full year earnings showing higher net income and earnings per share even as sales declined, helped by foreign exchange gains and contributions from Agro &amp; Life Solutions and ICT &amp; Mobility Solutions.</p>
<div class="lb-trans"><p>住友化学公司（TSE:4005）刚刚公布了全年的财报，显示出净收入和每股收益的增长，尽管销售额有所下降，这得益于外汇收益以及农业与生命解决方案和信息通信与移动解决方案的贡献。</p>
</div><p>See our latest analysis for Sumitomo Chemical Company.</p>
<div class="lb-trans"><p>查看我们对住友化学公司的最新分析。</p>
</div><p>The stock has pulled back 3.66% on a 1-day share price return to ¥600.8 after its earnings release, but a 32.98% year to date share price return and 81.34% 1-year total shareholder return suggest momentum has been building as investors reassess earnings quality, currency sensitivity and recent moves such as the planned Koei Chemical share exchange.</p>
<div class="lb-trans"><p>在财报发布后，股价回落了 3.66%，1 天的股价回报为¥600.8，但年初至今的股价回报为 32.98%，1 年的总股东回报为 81.34%，这表明随着投资者重新评估盈利质量、货币敏感性以及近期计划的 Koei Chemical 股权交换等举措，市场动能正在积聚。</p>
</div><p>If Sumitomo Chemical's rebound has caught your eye, this could be a good moment to look at other opportunities. Consider using our screener of 34 power grid technology and infrastructure stocks for potential long term themes tied to infrastructure and materials demand.</p>
<div class="lb-trans"><p>如果住友化学的反弹引起了你的注意，这可能是考虑其他机会的好时机。考虑使用我们对 34 只电网技术和基础设施股票的筛选器，以寻找与基础设施和材料需求相关的潜在长期主题。</p>
</div><p>The market reaction has been strong, yet the stock still trades only slightly below the latest analyst price target and appears to carry a significant intrinsic discount. This raises the question: is this a genuine opportunity, or is future growth already priced in?</p>
<div class="lb-trans"><p>市场反应强劲，但该股仍仅略低于最新的分析师目标价，并且似乎存在显著的内在折扣。这引发了一个问题：这是一个真正的机会，还是未来的增长已经被定价？</p>
</div><h2>Most Popular Narrative: 2% Overvalued</h2>
<div class="lb-trans"><h2>最受欢迎的叙述：高估 2%</h2>
</div><p>The most followed narrative pegs Sumitomo Chemical's fair value at ¥589.7, slightly below the last close of ¥600.8. This implies only a modest premium and puts the focus squarely on the earnings and margin story behind that figure.</p>
<div class="lb-trans"><p>最受关注的叙述将住友化学的公允价值定为¥589.7，略低于最后收盘价¥600.8。这意味着只有适度的溢价，并将焦点完全放在该数字背后的盈利和利润率故事上。</p>
</div><blockquote>
<p><em>Recovery in profitability across key segments (Agro &amp; Life Solutions, Essential &amp; Green Materials, ICT &amp; Mobility Solutions) reflects improved operational efficiency, product mix optimization, and R&amp;D-driven new product launches (e.g., Orgovyx, Gemtesa, INDIFLIN), supporting the potential for higher long-term revenue and net margins.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>关键领域（农业与生命解决方案、基本与绿色材料、信息通信与移动解决方案）盈利能力的恢复反映了运营效率的提高、产品组合的优化以及以研发驱动的新产品推出（例如，Orgovyx、Gemtesa、INDIFLIN），支持长期收入和净利润率的提升潜力。</em></p>
</blockquote>
</div><p><em>Read the complete narrative.</em></p>
<div class="lb-trans"><p><em>阅读完整叙述。</em></p>
</div><p>Analysts are baking in steady top line, slightly slimmer margins, and a richer future earnings multiple, all filtered through a 7.9% discount rate. This raises the question of which growth, profitability and valuation assumptions need to align for that fair value to hold up.</p>
<div class="lb-trans"><p>分析师们预计稳定的收入、略微收窄的利润率和更高的未来盈利倍数，所有这些都经过 7.9% 的折现率过滤。这引发了一个问题：哪些增长、盈利能力和估值假设需要对齐，以使该公允价值保持稳定。</p>
</div><p><strong>Result: Fair Value of ¥589.7 (OVERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值为¥589.7（高估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读叙述，了解预测背后的原因。</p>
</div><p>However, there are clear pressure points, including weaker petrochemicals margins and rising inventories in Agro &amp; Life Solutions, that could challenge the earnings and valuation narrative investors are watching.</p>
<div class="lb-trans"><p>然而，明显存在压力点，包括石化利润率疲软和农业与生命解决方案库存上升，这可能会挑战投资者关注的盈利和估值叙述。</p>
</div><p>Find out about the key risks to this Sumitomo Chemical Company narrative.</p>
<div class="lb-trans"><p>了解住友化学公司叙述的关键风险。</p>
</div><h2>Another View: Earnings Power Versus Market Multiple</h2>
<div class="lb-trans"><h2>另一种观点：盈利能力与市场倍数</h2>
</div><p>Analysts see Sumitomo Chemical as 2% overvalued at ¥589.7 based on their earnings model, yet the stock trades at a P/E of 16.3x versus a JP Chemicals average of 14.2x and a fair ratio of 20.3x. That gap hints at both upside potential and re rating risk. Which side of that trade are you on?</p>
<div class="lb-trans"><p>分析师认为住友化学在其盈利模型下高估 2%，公允价值为¥589.7，而该股的市盈率为 16.3 倍，JP 化学平均为 14.2 倍，公允比率为 20.3 倍。这个差距暗示了上行潜力和重新评级风险。你站在哪一边？</p>
</div><p>See what the numbers say about this price — find out in our valuation breakdown.</p>
<div class="lb-trans"><p>查看数字对这一价格的看法——在我们的估值分析中了解更多。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b80c179c-5115-4da9-9663-b331424c1556/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTE4" alt="" original-src="https://images.simplywall.st/company/b80c179c-5115-4da9-9663-b331424c1556/chart/pe-multiple-vs-industry?date=2026-05-18"/></p>
<p>TSE:4005 P/E Ratio as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 TSE:4005 市盈率</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><p>If the mix of risks and rewards here feels finely balanced, do not wait for the crowd to decide for you. Review the full breakdown of 3 key rewards and 3 important warning signs.</p>
<div class="lb-trans"><p>如果这里的风险与回报的组合感觉微妙平衡，不要等到人群为你做决定。查看 3 个关键回报和 3 个重要警告信号的完整分析。</p>
</div><h2>Looking For More Investment Ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>If Sumitomo Chemical is already on your radar, do not stop there. The market is full of other stocks that could better fit your risk and return preferences.</p>
<div class="lb-trans"><p>如果住友化学已经在你的雷达上，不要止步于此。市场上还有其他股票可能更符合你的风险和回报偏好。</p>
</div><ul>
<li>Target long term compounding potential by reviewing companies flagged as 19 high quality undervalued stocks with solid earnings support and room for sentiment to improve.</li>
<li>Strengthen your income stream by scanning 41 dividend fortresses that combine higher yields with business models focused on sustaining regular payouts.</li>
<li>Get ahead of the crowd by checking the screener containing 55 high quality undiscovered gems where strong fundamentals have yet to attract wide market attention.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过审查被标记为 19 只高质量低估股票的公司，目标长期复合潜力，这些公司有坚实的盈利支持和改善情绪的空间。</li>
<li>通过扫描 41 只高股息股票来增强你的收入流，这些股票结合了更高的收益率和专注于维持定期支付的商业模式。</li>
<li>通过检查包含 55 只高质量未被发现的宝藏的筛选器，抢先于人群，这些股票的强大基本面尚未吸引广泛的市场关注。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不应被视为财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们的目标是为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：在一个地方管理所有股票投资组合</strong></h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>而且是免费的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 连接无限数量的投资组合，并以一种货币查看你的总额</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟踪你股票的公允价值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免费试用演示投资组合</p>
</div>

住友化学（TSE:4005）在年度收益反弹后的估值分析